Synapse - Robert Motzer

Results (160)

Metastatic chromophobe renal cell carcinoma: Presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes

Journal Article

Ged, Y.; Chen, Y. B.; Knezevic, A.; Casuscelli, J.; Redzematovic, A.; DiNatale, R. G.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; more...
Clinical Genitourinary Cancer (2019)

Fulltext@MSK | Save

Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: Data from a randomized phase III trial

Journal Article

Hakimi, A. A.; Voss, M. H.; Kuo, F.; Sanchez, A.; Liu, M.; Nixon, B. G.; Vuong, L.; Ostrovnaya, I.; Chen, Y. B.; Reuter, V.; more...
Cancer Discovery (2019)

Fulltext@MSK | Save

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Research Letter

Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
Nature Genetics (2019)

Fulltext@MSK | Save

PTEN expression, not mutation status in TSC1, TSC2, or mTOR, correlates with the outcome on everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 trial

Journal Article

Voss, M. H.; Chen, D.; Reising, A.; Marker, M.; Shi, J.; Xu, J.; Ostrovnaya, I.; Seshan, V. E.; Redzematovic, A.; Chen, Y. B.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis

Meeting Abstract

Voss, M. H.; Kuo, F.; Sanchez, A.; Ostrovnaya, I.; Cheng, Y.; Patel, P.; Marker, M.; Reising, A.; Chan, T. A. T.; Motzer, R. J.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)

Meeting Abstract

McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant

Meeting Abstract

Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)

Meeting Abstract

Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial

Meeting Abstract

Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save